R21TW013153
Project Grant
Overview
Grant Description
INNOVATIONS IN MOLECULAR DIAGNOSTIC APPROACHES FOR HIV-ASSOCIATED LYMPHOMAS. - AGGRESSIVE B-CELL LYMPHOMAS ARE INCREASINGLY COMMON BUT UNDERDIAGNOSED IN PEOPLE WITH HIV (PWH) IN MALAWI. IN 2013, WE ESTABLISHED THE KAMUZU CENTRAL HOSPITAL (KCH) LYMPHOMA STUDY, A PROSPECTIVE OBSERVATION COHORT OF PATHOLOGICALLY CONFIRMED LYMPHOMAS IN MALAWI THAT INCLUDES UNIFORM DIAGNOSIS, STANDARDOF-CARE THERAPY, AND FIVE-YEAR CLINICAL AND LABORATORY FOLLOW-UP FOR PARTICIPANTS. WE HAVE SHOWN THAT TREATING LYMPHOMA IN PWH IS SAFE AND EFFECTIVE, AND THE LYMPHOMA STUDY HAS BECOME A LEADING REGIONAL RESOURCE FOR CLINICAL AND TRANSLATIONAL RESEARCH STUDIES OF HIV-ASSOCIATED LYMPHOMAS. HOWEVER, CURRENT DIAGNOSTIC STRATEGIES ARE PROHIBITIVELY EXPENSIVE WHICH LIMITS THE REACH OF EFFECTIVE LYMPHOMA CARE, AND THE PIVOTAL GENOMIC STUDIES FROM OUR GROUP ARE PRIMARILY BEING PERFORMED OUTSIDE OF MALAWI. HEREIN, WE PROPOSE LONGREAD NANOPORE SEQUENCING APPROACHES THAT REQUIRE MINIMAL CAPITAL INVESTMENT, AND LIMITED LAB INFRASTRUCTURE TO MOLECULARLY DIAGNOSE AND SUBCLASSIFY COMMON AGGRESSIVE B-CELL LYMPHOMAS IN PWH. THE PROPOSAL BUILDS ON OUR WORK IN HIV-ASSOCIATED LYMPHOMAS, CUTTING-EDGE EXPERTISE IN LONG-READ NANOPORE SEQUENCING, AND, MOST CRITICALLY, AND RESEARCH INFRASTRUCTURE AT THE UNC-PROJECT MALAWI RESEARCH SITE. WE AIM TO DEVELOP EFFECTIVE, RESOURCE-APPROPRIATE DIAGNOSTIC TOOLS AND SUBSEQUENTLY INVESTIGATE IMPLEMENTATION OF NANOPORE SEQUENCING ACROSS A NETWORK OF SITES WHILE PERFORMING ONGOING CLINICAL, COMPUTATIONAL, AND ECONOMIC ASSESSMENTS. THIS PROJECT BUILDS CAPACITY TO PERFORM ADVANCED MOLECULAR CHARACTERIZATION OF HIV-ASSOCIATED LYMPHOMAS IN MALAWI AND LEVERAGES ONGOING CLINICAL, RESEARCH, AND TRAINING PROGRAMS.
Funding Goals
THE JOHN E. FOGARTY INTERNATIONAL CENTER (FIC) SUPPORTS RESEARCH AND RESEARCH TRAINING TO REDUCE DISPARITIES IN GLOBAL HEALTH AND TO FOSTER PARTNERSHIPS BETWEEN U.S. SCIENTISTS AND THEIR COUNTERPARTS ABROAD. FIC SUPPORTS BASIC BIOLOGICAL, BEHAVIORAL, AND SOCIAL SCIENCE RESEARCH, AS WELL AS RELATED RESEARCH TRAINING AND CAREER DEVELOPMENT. THE RESEARCH PORTFOLIO IS DIVIDED INTO SEVERAL PROGRAMS THAT SUPPORT A WIDE VARIETY OF FUNDING MECHANISMS TO MEET PROGRAMMATIC OBJECTIVES.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Chapel Hill,
North Carolina
27599
United States
Geographic Scope
Single Zip Code
University Of North Carolina At Chapel Hill was awarded
NanoPore Sequencing for HIV-Associated Lymphoma Diagnosis in Malawi
Project Grant R21TW013153
worth $344,203
from Fogarty International Center in September 2025 with work to be completed primarily in Chapel Hill North Carolina United States.
The grant
has a duration of 2 years and
was awarded through assistance program 93.989 International Research and Research Training.
The Project Grant was awarded through grant opportunity HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 8/20/25
Period of Performance
9/1/25
Start Date
8/31/27
End Date
Funding Split
$344.2K
Federal Obligation
$0.0
Non-Federal Obligation
$344.2K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
R21TW013153
SAI Number
R21TW013153-814565640
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NF00 NIH Fogarty International Center
Funding Office
75NF00 NIH Fogarty International Center
Awardee UEI
D3LHU66KBLD5
Awardee CAGE
4B856
Performance District
NC-04
Senators
Thom Tillis
Ted Budd
Ted Budd
Modified: 8/20/25